Literature DB >> 25576089

A pivotal moment in Alzheimer's disease and dementia: how global unity of purpose and action can beat the disease by 2025.

George Vradenburg1.   

Abstract

The world is at a pivotal moment in the global fight against Alzheimer's disease, a disease that by 2013 affected 44.4 million people globally and is expected to affect 75.6 million by 2030. France, Australia, Japan, US and Great Britain are among the countries that have adopted national policies to address the growing numbers. Multilateral organizations have also prioritized the disease, and possibly most significantly, the G8, under British Prime Minister David Cameron's leadership, set its focus on dementia starting December 2013. Despite the growing attention, the response has not been commensurate with the urgency of the situation, and we need to promote comprehensive collaboration that catalyzes the development of new treatments, initiates the creation of innovative financial models for research and drives the utilization of technological innovation with the aim to reverse the trajectory of this devastating disease.

Entities:  

Keywords:  Alzheimer’s disease; advocacy; clinical trials; dementia; drug development; national plan; pharmaceuticals; regulatory; research and development

Mesh:

Substances:

Year:  2015        PMID: 25576089     DOI: 10.1586/14737175.2015.995638

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  8 in total

Review 1.  A short perspective on the long road to effective treatments for Alzheimer's disease.

Authors:  David S Reynolds
Journal:  Br J Pharmacol       Date:  2019-03-01       Impact factor: 8.739

2.  Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred.

Authors:  J T Fuller; A Cronin-Golomb; J R Gatchel; D J Norton; E Guzmán-Vélez; H I L Jacobs; B Hanseeuw; E Pardilla-Delgado; A Artola; A Baena; Y Bocanegra; K S Kosik; K Chen; P N Tariot; K Johnson; R A Sperling; E M Reiman; F Lopera; Y T Quiroz
Journal:  J Prev Alzheimers Dis       Date:  2019

Review 3.  Drug development in Alzheimer's disease: the path to 2025.

Authors:  Jeffrey Cummings; Paul S Aisen; Bruno DuBois; Lutz Frölich; Clifford R Jack; Roy W Jones; John C Morris; Joel Raskin; Sherie A Dowsett; Philip Scheltens
Journal:  Alzheimers Res Ther       Date:  2016-09-20       Impact factor: 6.982

Review 4.  Iron Dysregulation and Dormant Microbes as Causative Agents for Impaired Blood Rheology and Pathological Clotting in Alzheimer's Type Dementia.

Authors:  Lesha Pretorius; Douglas B Kell; Etheresia Pretorius
Journal:  Front Neurosci       Date:  2018-11-16       Impact factor: 4.677

5.  The price of progress: Funding and financing Alzheimer's disease drug development.

Authors:  Jeffrey Cummings; Carl Reiber; Parvesh Kumar
Journal:  Alzheimers Dement (N Y)       Date:  2018-06-13

6.  Re-thinking Alzheimer's disease therapeutic targets using gene-based tests.

Authors:  Man Ki Kwok; Shi Lin Lin; C Mary Schooling
Journal:  EBioMedicine       Date:  2018-10-09       Impact factor: 8.143

7.  Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial.

Authors:  Robert Howard; Olga Zubko; Rosie Bradley; Emma Harper; Lynn Pank; John O'Brien; Chris Fox; Naji Tabet; Gill Livingston; Peter Bentham; Rupert McShane; Alistair Burns; Craig Ritchie; Suzanne Reeves; Simon Lovestone; Clive Ballard; Wendy Noble; Ramin Nilforooshan; Gordon Wilcock; Richard Gray
Journal:  JAMA Neurol       Date:  2020-02-01       Impact factor: 18.302

Review 8.  A Bacterial Component to Alzheimer's-Type Dementia Seen via a Systems Biology Approach that Links Iron Dysregulation and Inflammagen Shedding to Disease.

Authors:  Etheresia Pretorius; Janette Bester; Douglas B Kell
Journal:  J Alzheimers Dis       Date:  2016-06-18       Impact factor: 4.472

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.